Eli Lilly and Company and Scorpion Therapeutics, Inc., a private biotechnology company developing small molecule precision oncology therapies, announced on Jan. 13 a definitive agreement for Lilly to acquire Scorpion’s PI3Kα inhibitor program STX-478.